Pharma time-to-market reduced thanks to more efficient submission document publishing services
The merger with Regulis Consulting Limited in the UK increases the market share of PharmaLex in this important market
Frankfurt, Germany – 30th June 2020: PharmaLex Group, a leading provider of specialised services for the pharma, biotech and medical device industries worldwide, have completed the legal merger with Regulis Consulting Limited (Regulis) in the United Kingdom.
Regulis was founded in 2001 and is now a prominent consultancy company with vast experience of working mainly with companies specialising in pharmaceuticals, biopharmaceuticals, medical devices and cosmetics. Their team of expert pharmaceutical consultants assist in the European and Global arenas and have a strong reputation for obtaining fast, high quality regulatory approvals, as well as providing highly dependable pharmacovigilance, vigilance and GMP / GDP client solutions.
By joining forces with Regulis, PharmaLex will strengthen its already significant footprint in the UK and further increase its market share in this key market.
“The merger with PharmaLex brings significant mutual benefits”, explained Kim Wharton, Founder and Managing Director, Regulis. “Our services in Regulatory Affairs, Pharmacovigilance and Quality Assurance align perfectly within the PharmaLex portfolio. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis and our clients”, he added.
“PharmaLex and Regulis joining forces offers tremendous potential to our complementary client bases and will contribute further to the successful development of our significant operations and business in the UK and Ireland”, explained Jon Jeffery, Head UK / Ireland Region and Managing Director, PharmaLex UK. “Our positive cultures and values are very well-matched and considering the strong organic growth of both businesses over recent years, expanding PharmaLex in this region with the similarly motivated and well-regarded team at Regulis should bring further, exciting opportunities for all”, added Dr. Thomas Dobmeyer, CEO PharmaLex.
-Ends-
About PharmaLex <Confidence beyond compliance>:
PharmaLex is a leading provider of specialised services for the pharma, biotech and medical device industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.
The PharmaLex Group now has over 1000 employees, with 34 offices in 21 countries and more than 600 satisfied clients worldwide.
For further information, please contact:
Ms. Eva Keck
PharmaLex GmbH; Director, Business Development Operations
eva.keck@pharmalex.com
+49 621 18 15 38 0
Harrlachweg 6
68163 Mannheim
Germany
Related posts
